FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical ecosystem

FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical ecosystem

Acronym

FACILITATE

Description of the granted funding

FACILITATE is a project built on a patient-centered, data-driven, technological platform where an innovative data sharing and re-use process allows the returning of clinical trial data to study participants within a GDPR compliant and approved ethical framework. FACILITATE starts-off by providing clear rules in a trusted ethical, legal and regulatory ecosystem before engaging patients as data generators. This avoids the current situation where clinical data are siloed in separate repositories without any possibility to be used beyond their original single-sided purpose. FACILITATE will provide the technological solutions to comply with GDPR in medical research by building on the empowered stakeholders' willingness to share and re-use their data. The FACILITATE Consortium was constituted by drawing from a broad range of capacities to tackle the ambitious challenges related to future clinical trials, such as preventive, long-term and real-world evidence trials. The Consortium took an innovative approach to the data return to study participants by asking them what they needed to be implemented to feel in a trusted ecosystem. This required all Consortium participants to leverage on their existing networks to bring together stakeholders at all levels in the decision-making chain, including patients, healthcare professionals, software designers, clinical trials repositories processors and controllers, ethicists, lawyers and other active regulators. Having obtained a consent on the data portability FACILITATE will re-use and cross-reference them with those contained in other repositories including RWE data captured across multiple settings and devices. FACILITATE will last 4 years and will participate in the extended Pilot on Open Research Data of Horizon 2020. Its strategy represents a unique and innovative opportunity for medicines drug development and regulation to better understand the clinics of diseases, and to evaluate the effectiveness of products in the healthcare system.
Show more

Starting year

2022

End year

2025

Granted funding

215 250 €
Participant
UNIWERSYTET JAGIELLONSKI (PL)
77 750 €
Participant
ST ANTONIUS HOSPITAL GRONAU GMBH (DE)
87 938.75 €
Participant
ADERA SAS (FR)
91 500 €
Participant
MDSOL EUROPE LTD (UK)
Participant
INPECO TPM SRL (IT)
Third party
ROCHE DIAGNOSTICS INTERNATIONAL AG (CH)
Participant
PRIVANOVA SAS (FR)
290 000 €
Participant
PRIVREDNO DRUSTVO ZENTRIX LAB DRUSTVO SA OGRANICENOM ODGOVORNOSCU PANCEVO (RS)
268 375 €
Participant
INPECO SA (CH)
Participant
ODYSSEUS DATA SERVICES SRO (CZ)
381 625 €
Participant
BAYER AKTIENGESELLSCHAFT (DE)
Participant
AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO DI MODENA (IT)
72 500 €
Participant
TAKEDA PHARMACEUTICALS INTERNATIONAL AG (CH)
Participant
ABBVIE INC (US)
Participant
SPITALUL CLINIC COLENTINA BUCURESTI (RO)
54 675 €
Participant
EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION (FR)
140 250 €
Participant
ASSOCIAZIONE CITTADINANZATTIVA ONLUS (IT)
175 225 €
Participant
BRISTOL-MYERS SQUIBB COMPANY CORP (US)
Participant
ALMIRALL SA (ES)
Participant
INSTITUT ZA MEDICINSKA ISTRA IVANJA (RS)
83 062.5 €
Participant
PFIZER LIMITED (UK)
Participant
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR)
Participant
MEDIZINISCHE UNIVERSITAT GRAZ (AT)
134 625 €
Participant
UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA (IT)
592 348.75 €
Coordinator
ACCADEMIA EUROPEA DI BOLZANO (IT)
275 250 €
Participant
VRIJE UNIVERSITEIT BRUSSEL (BE)
237 500 €
Participant
ASTRAZENECA AB (SE)
Participant
INSTITUT DE RECHERCHES SERVIER (FR)
Participant

Amount granted

3 260 000 €

Funder

European Union

Funding instrument

Research and Innovation action

Framework programme

Horizon 2020 Framework Programme

Call

Programme part
Health (5290)
Innovative Medicines Initiative 2 (IMI2) (5312)
Topic
Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework (IMI2-2020-23-01)
Call ID
H2020-JTI-IMI2-2020-23-two-stage

Other information

Funding decision number

101034366
FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical ecosystem - Research.fi